Generic Name and Formulations:
Desvenlafaxine (as succinate) 25mg, 50mg, 100mg; ext-rel tabs.
Indications for PRISTIQ:
Major depressive disorder.
Swallow whole. 50mg once daily. Moderate renal impairment (CrCl 30–50mL/min): max 50mg/day. Severe renal impairment (CrCl <30mL/min), ESRD: max 25mg daily or 50mg every other day. Do not give supplemental dose after dialysis. Moderate-to-severe hepatic impairment: max 100mg/day. Withdraw gradually.
During or within 14 days of MAOIs; do not start an MAOI during or within 7 days of desvenlafaxine. Concomitant linezolid or IV methylene blue.
Suicidal thoughts and behaviors.
Increased risk of suicidal thinking or behavior; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue immediately if occurs. Monitor BP; reduce dose or discontinue if elevated BP persists. Cardio- or cerebrovascular disease. Angle closure glaucoma. Avoid in untreated anatomically narrow angles. History of mania/hypomania. Seizure disorder. Volume depleted. Renal or hepatic impairment. Avoid abrupt cessation. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (avoid in 3rd trimester); see full labeling for effects on neonate. Nursing mothers.
See Contraindications. Avoid alcohol, concomitant venlafaxine, other forms of desvenlafaxine. Increased risk of serotonin syndrome with other serotonergic drugs (eg, other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs such as linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin, or other drugs that affect coagulation; monitor closely. May affect CYP2D6 substrates (eg, desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine); reduce dose by up to ½ if concomitant with desvenlafaxine 400mg dose. May cause false (+) urine immunoassay screening tests for PCP and amphetamine.
Nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, specific male sexual dysfunction; hyponatremia (esp. in elderly); rare: interstitial lung disease or eosinophilic pneumonia (consider discontinuing if occurs).
Tabs 25mg—30; 50mg, 100mg—14, 30, 90
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML